CYBRD1 and pancreatic neoplasm: Furthermore, NOSTRIN was found to be a potential negative regulator of disease aggressiveness in pancreatic cancer and CYBRD1 was identified as part of an iron regulatory gene signature that predicts outcome in BC [53, 54].